Back to Journals » OncoTargets and Therapy » Volume 7

Gli3 silencing enhances cyclopamine suppressive effects on ovarian cancer

Authors Liu H, Dong Z

Received 10 November 2013

Accepted for publication 24 January 2014

Published 30 October 2014 Volume 2014:7 Pages 2007—2011

DOI https://doi.org/10.2147/OTT.S57346

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4


Hai-Yan Liu, Zheng Dong

Department of Gynecology, First Affiliated Hospital of Liaoning Medical College, Jinzhou, People’s Republic of China

Abstract: Ovarian cancer is a leading gynecological malignancy associated with high mortality. Hedgehog signaling has been found to be important for cell proliferation and tumor growth for multiple cancers, including ovarian cancer. The present study showed that the drug cyclopamine, which blocks the hedgehog signaling pathway, could reduce cancer cell growth and proliferation and induce cell apoptosis. In addition, the silencing of the glioma-associated oncogene (Gli)3, a downstream component of the hedgehog signaling pathway, could further enhance the antitumor effects of cyclopamine. Our results suggest that Gli3 may act as resistance to cyclopamine’s effect on tumor growth. The combined treatment of cyclopamine application and Gli3 silencing therapy, therefore, may provide novel directions for clinical management of ovarian cancer.

Keywords: ovarian cancer, hedgehog, cyclopamine, proliferation, apoptosis, Gli3

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]